Lifitegrast Approval Status
- FDA approved: No
- Generic name: lifitegrast
- Company: Shire US, Inc.
- Treatment for: Dry Eye Disease
Lifitegrast is an investigational integrin antagonist for the topical treatment of dry eye disease.
In October 2015, Shire plc announced the U.S. Food and Drug Administration (FDA) had requested an additional clinical study as part of a complete response letter (CRL) to the company’s new drug application for lifitegrast.
Development Status and FDA Approval Process for lifitegrast
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.